{
    "clinical_study": {
        "@rank": "127792", 
        "arm_group": [
            {
                "arm_group_label": "Participants with severe renal insufficiency", 
                "arm_group_type": "Experimental", 
                "description": "Participants with severe renal insufficiency will receive once daily oral dose of 100 mg MK-5172 and 50 mg MK-8742 for 10 days."
            }, 
            {
                "arm_group_label": "Healthy Matched Controls", 
                "arm_group_type": "Experimental", 
                "description": "Healthy controls matched to participants with ESRD and severe renal insufficiency (for age, body mass index, and gender) will receive once daily oral dose of 100 mg MK-5172 and 50 mg MK-8742 for 10 days."
            }, 
            {
                "arm_group_label": "Participants with ESRD on HD", 
                "arm_group_type": "Experimental", 
                "description": "Participants with ESRD on HD will receive once daily oral dose of 100 mg MK-5172 and 50 mg MK-8742 for 10 days."
            }
        ], 
        "brief_summary": {
            "textblock": "MK-5172 and MK-8742 are being studied as the principal components of combination oral\n      therapy for hepatitis C virus (HCV).\n\n      The study will examine the pharmacokinetic (PK) profiles of MK-5172 and MK-8742 following 10\n      days of dosing in participants with end stage renal disease (ESRD) on hemodialysis (HD) or\n      severe renal impairment.  Both groups will be compared to healthy matched controls."
        }, 
        "brief_title": "The Pharmacokinetics of MK-5172 and MK-8742 in Participants With Renal Insufficiency (MK-5172-050)", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Chronic Hepatitis C", 
            "Renal Impairment"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Renal Insufficiency", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All Participants\n\n          -  For a female of childbearing potential: either be sexually inactive (abstinent) for\n             14 days prior to the first dose and throughout the study or be using an acceptable\n             birth control method. Females of non-childbearing potential must have undergone a\n             sterilization procedure at least 6 months prior to the first dose\n\n          -  Non-vasectomized male participants must agree to use a condom with spermicide or\n             abstain from sexual intercourse during the trial and for 90 days after stopping the\n             study medication and agree not to donate sperm during this time period Participants\n             with ESRD on HD\n\n          -  Maintained on a stable regimen of HD within 3 months prior to first dosing\n             Participants with Severe Renal Impairment\n\n          -  Estimated glomerular filtration rate (eGFR) at screening is < 30 mL/min/1.73m^2\n             Healthy Controls\n\n          -  Participant is within \u00b1 10 years of the mean age and within 10% of the mean body mass\n             index of severe renal impairment participants\n\n          -  eGFR at screening is >=80 mL/min/1.73m^2\n\n        Exclusion Criteria:\n\n        All Participants\n\n          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,\n             hematological, gastrointestinal, endocrine, immunologic, dermatologic, or\n             neurological disease whose current condition is considered unstable\n\n          -  History or presence of alcoholism and drug abuse within the past 6 months\n\n          -  Female participants who are pregnant or lactating\n\n          -  Regular user of any medication (including over the counter) that would significantly\n             alter GFR\n\n          -  Donation of blood or significant blood loss within 56 days prior to the first dose of\n             study medication(s)\n\n          -  Plasma donation within 7 days prior to the first dose of study medication(s)\n\n          -  A renal transplant or nephrectomy Participants with ESRD or Severe Renal\n             Insufficiency\n\n          -  Rapidly fluctuating renal function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937975", 
            "org_study_id": "5172-050"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Participants with severe renal insufficiency", 
                    "Healthy Matched Controls", 
                    "Participants with ESRD on HD"
                ], 
                "description": "100 mg oral tablet administered once a day for 10 days", 
                "intervention_name": "MK-5172", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Participants with severe renal insufficiency", 
                    "Healthy Matched Controls", 
                    "Participants with ESRD on HD"
                ], 
                "description": "50 mg oral tablet administered once a day for 10 days", 
                "intervention_name": "MK-8742", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 6, 2014", 
        "number_of_arms": "3", 
        "official_title": "An Open-Label Study to Investigate the Pharmacokinetics of MK-5172 and MK-8742 in Subjects With Renal Insufficiency", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the concentration-time curve from 0 to 24 hours postdose (AUC 0-24) of MK-5172 and MK-8742", 
                "safety_issue": "No", 
                "time_frame": "0 up to 24 hours postdose"
            }, 
            {
                "measure": "Plasma concentration at 24 hours postdose (C24) of MK-5172 and MK-8742", 
                "safety_issue": "No", 
                "time_frame": "24 hours postdose"
            }, 
            {
                "measure": "Maximum plasma concentration (Cmax) of MK-5172 and MK-8742", 
                "safety_issue": "No", 
                "time_frame": "0 up to 120 hours postdose"
            }, 
            {
                "measure": "Time to maximum plasma concentration (Tmax) of MK-5172 and MK-8742", 
                "safety_issue": "No", 
                "time_frame": "0 up to 120 hours postdose"
            }, 
            {
                "measure": "Terminal phase half-life (T1/2) of MK-5172 and MK-8742", 
                "safety_issue": "No", 
                "time_frame": "0 up to 120 hours postdose"
            }, 
            {
                "measure": "Apparent clearance after extravascular administration (CL/F) of MK-5172 and MK-8742", 
                "safety_issue": "No", 
                "time_frame": "0 up to 120 hours postdose"
            }, 
            {
                "measure": "Apparent volume of distribution after extravascular administration (V/F) of MK-5172 and MK-8742", 
                "safety_issue": "No", 
                "time_frame": "0 up to 120 hours postdose"
            }
        ], 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937975"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}